Skip to main navigation

Skip to Content

Stock
Financials
- SEC Filings
- Financial Reports
News & Events
Corporate Governance
Our Company
IR Resources

Press Releases

Year

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Mar 02, 2023

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Feb 07, 2023

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Nov 07, 2022

Genenta Provides First Half 2022 Business Update and Financial Results

Oct 24, 2022

Genenta to Present at Upcoming Scientific and Investor Conferences

Oct 05, 2022

Genenta to Present at Upcoming Investor Conferences

Sep 07, 2022

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Jul 25, 2022

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 13, 2022

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 09, 2022

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 04, 2022

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Next page
Last page

Displaying 11 - 20 of 59

Investor Contact

RSS Feeds

Print

ITALY
Dibit – San Raffaele Hospital
Via Olgettina, 58
20132 Milano

UNITED STATES
LaunchLabs – Alexandria Center
430 East 29th Street
New York NY 10016

PARTNERS

genenta-img-san_raffaele

© 2024 Genenta Science. All rights reserved - - Terms and conditions - Privacy Policy